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Introduction: Renal transplantation has been performed with increasing frequency, and interventions to preserve graft
function and integrity have been steadily increasing. This study examines the outcomes of endovascular therapy based on
indication for renal transplant allograft salvage.
Methods: A prospective transplant registry was queried for all patients undergoing endovascular interventions for trans-
plant allograft salvage from 2002 to 2011. Demographics, perioperative data, and transplant function outcomes were
extracted and analyzed.
Results: Among 34 renal transplant recipients (62% men) who underwent endovascular interventions for graft salvage, the
mean age was 48.2 years (range, 18-74 years). The indications for intervention included worsening renal function in 15,
renovascular hypertension in 11, and structural abnormalities identiﬁed on noninvasive imaging in eight. Transluminal
angioplasty with and without stenting was done in 26 patients: 14 patients (41.2%) with signiﬁcant transplant stenosis,
11 (32.4%) with peripheral arterial disease in proximal iliac vessels, and one patient with iliac dissection. Five arterio-
venous ﬁstulas and two pseudoaneurysms required embolization. One patient required lysis for deep venous thrombosis
causing obstruction of allograft outﬂow. There were no periprocedural deaths, and 30-day morbidity was 17.6%. Renal
function improved or stabilized in 67% of patients with worsening renal function. Better blood pressure control was
achieved in patients with renovascular hypertension. Mean follow-up was 4.2 years. There were no signiﬁcant differences
in transplant allograft survival during the duration of follow-up based on primary indication for endovascular inter-
vention, but transplant graft survival at follow-up was signiﬁcantly better in patients with renovascular hypertension at
the initial endovascular intervention.
Conclusions: Endovascular salvage of renal allograft transplants can be safely done for various indications. The maximum
beneﬁt in renal function as assessed by serum creatinine and control of blood pressure is seen in patients with worsening
renal function and in the presence of renovascular hypertension, respectively. Long-term transplant graft function
was signiﬁcantly better in patients with renovascular hypertension at the initial endovascular intervention. (J Vasc Surg
2013;57:1621-7.)The number of renal transplantations performed annu-
ally in the United States has doubled in the last decade.1
Because these patients need strict surveillance of their renal
transplant allograft to ensure long-term graft function and
freedom from dialysis, vascular procedures have become
increasingly common in this population. Various patholo-
gies can affect graft function, including acute or chronic
rejection, infections, and decreased blood ﬂow to the allo-
graft due to transplant renal artery stenosis (TRAS) or
proximal iliac stenosis. Graft function can also be affected
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Surgical therapy2,3 has been the traditional mainstay of
treatment of vascular pathology or structural threats to the
integrity of a renal transplant allograft, but with the advent
of endovascular techniques, treatment of TRAS, proximal
iliac stenosis, or anomalies such as AVFs and pseudoaneur-
ysms are being treated using an endovascular approach.
Surgery is currently reserved for failure of endovascular
therapy, refractory pathology, or in a minority of patients
who have lesions that are not amenable to endovascular
procedures.
Because transplantation in the elderly and diabetic pop-
ulations has become more prevalent, increased aortoiliac
occlusive disease (AIOD) that mimics TRAS has been
observed. TRAS is associated with graft loss,4 so it is imper-
ative to examine the long-term role of less invasive thera-
pies on allograft salvage in this high-risk patient
population. Our study examined the short-term and
long-term outcomes of endovascular therapy based on
indication for renal transplant allograft salvage.
METHODS
A prospective transplant registry maintained at the
University of Michigan was queried for all patients1621
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The need for angiography was determined by the primary
transplant nephrology and surgery team for the investigation
of transplant allograft function or integrity. Before renal
transplant, the vascular evaluation comprised a complete
history and physical examination, including a detailed
vascular examination. Further investigations included
ankle-brachial indices, computed tomography angiography,
or magnetic resonance angiography, if indicated.
The clinical evaluation intervals after transplantation
were determined by transplant surgery and nephrologyd
typically 1 month, followed by every 3 months for the ﬁrst
2 years, followed by every 6 months for 2 years, and then
yearly. This reﬂects our institutional standards for trans-
plant patients postoperatively.
On the basis of our institutional experience with this
patient population, we have adopted the approach summa-
rized in Fig 1. The primary indications for interventions
included worsening renal function, renovascular hyperten-
sion, or structural abnormalities compromising graft func-
tion. Worsening renal function was deﬁned by RIFLE
criteria (Risk of renal dysfunction, Injury to the kidney,
Failure or Loss of kidney function, and End-stage
kidney disease),5 including worsening serum creatinine by
1.5- to two-times baseline and a decrease in glomerular
ﬁltration rate (GFR) to <25% to 50%. Patients with
complications of worsening renal function, such as ﬂuid
overload, congestive heart failure, or intractable peripheral
edema, were included in this group.
Renovascular hypertension (RV-HTN) was deﬁned as
persistent hypertension with increasing need for antihyper-
tensive medications and labile blood pressures refractory to
therapy in the setting of TRAS or proximal iliac stenosis on
noninvasive imaging (duplex ultrasound, magnetic reso-
nance imaging, or computed tomography). Patients were
also included in this group if they had admissions for hyper-
tensive crises or complications of hypertension, such as
ﬂash pulmonary edema in the setting of proximal stenosis.
Duplex ﬁndings suggestive of impaired ﬂow to the renal
transplant allograft included presence of pulsus parvus et
tardus waveform, elevated peak systolic velocities across
the stenotic site (>200 cm/s), elevated resistive indices
(>0.8), or a high-velocity jet >7.5 kHz, and distal turbu-
lence with >70% stenotic lesion in the transplant anasto-
mosis or proximal iliac artery.6,7 The signiﬁcance of the
stenotic lesion was determined intraoperatively using the
degree of stenosis on an angiogram or in most patients
using pressure gradients across the lesion. Percutaneous
transluminal angioplasty (PTA)/stenting procedures were
done when indicated in patients for a signiﬁcant pressure
gradient, deﬁned as >15 mm Hg systolic blood pressure
(SBP) or >10 mm Hg mean arterial pressure across the
stenotic lesion, or a >70% stenosis on an angiogram.
The medical records of the identiﬁed patients were
studied in detail to retrospectively collect relevant demo-
graphic, periprocedural, and follow-up data. Patient demo-
graphics collected included age, race, height, weight, body
mass index, medical comorbidities, American Society ofAnesthesiologists class, and smoking history. Details of
the endovascular intervention collected included type of
intervention, implants used, and use of contrast. Postoper-
ative morbidity and mortality were recorded for the in-
hospital stay. Need for secondary interventions, change in
renal function, improvement in control of hypertension,
need for dialysis, renal transplant allograft failure, and
need for transplant nephrectomy were abstracted from
long-term follow-up records.
Continuous variables were compared using the Student
t-test or one-way analysis of variance. Multiple comparisons
among more than two groups were made using Bonferroni
or Scheffe correction methods. The Fisher exact test was
used to compare categoric variables. Long-term renal
transplant allograft functional survival was determined for
various indications using Kaplan-Meier analysis and the
log-rank test. STATA 9 software (StataCorp LP, College
Station, Tex) was used for all statistical analysis. Statistical
signiﬁcance was identiﬁed for a P value #.05.
RESULTS
Among 2355 renal transplant recipients from 2002 to
2012, 65 underwent arteriograms to determine reasons
for a decline in graft function and after the ﬁndings on
noninvasive imaging. Of those, 34 patients (1.4% inci-
dence) had clinically signiﬁcant lesions on angiography
and underwent endovascular interventions for graft
salvage. The other 31 patients did not have clinically signif-
icant lesions, as determined by the degree of stenosis or the
pressure gradient, or did not have the structural abnormal-
ities as suggested by the noninvasive imaging. The cohort
was a mean age of 48.2 years (range, 18-74 years),
and 62% were men. The mean body mass index was
26.9 kg/m2 (range, 14.9-39.3 kg/m2). Table I summa-
rizes the patient demographics and medical comorbidities.
All patients were receiving immunosuppressants. Only six
patients had a prior diagnosis of peripheral arterial disease
(PAD).
The primary indications for intervention included
worsening renal function in 15 patients, RV-HTN in 11,
and structural abnormalities identiﬁed on noninvasive
imaging in eight (Table II). All interventions were per-
formed using femoral access. PTA, with and without stent-
ing, was done in 26 patients: 14 (41.2%) with signiﬁcant
transplant stenosis, 11 (32.4%) with PAD in proximal iliac
vessels, and one patient with iliac dissection. Five AVFs and
two pseudoaneurysms required embolization. One patient
required lysis for acute deep venous thrombosis of the right
common and external iliac vein extending to the femoral
vein.
The mean time from the renal transplant to the endo-
vascular intervention was 16.1 6 27.6 months. The inter-
ventions for TRAS were done on an average of 5 6
2.9 months after transplant, whereas the proximal iliac
stenoses presented much later, at 32.1 6 42.7 months
(P ¼ .042). There was no statistical signiﬁcance when
comparing time to endovascular intervention by primary
indication for procedure.
Fig 1. Algorithm for assessment of declining transplant allograft function. ACE-I, Angiotensin-converting enzyme
inhibitor; ARB, angiotensin receptor blocker; CT, computed tomography; HTN, hypertension; MRI, magnetic
resonance imaging.
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dioxide (CO2) angiography with minimal use of additional
contrast. The amount of contrast used ranged from 5 to
15 mL. This was typically needed if there was discordance
in the pressure gradient and CO2 angiography, or for
completion imaging. Purely iodinated contrast angiography
was done in 11 patients (32%), whereas only four had iso-
lated CO2 angiograms. No contrast nephropathy occurred
in the cohort. Overall technical success was 97%. One proce-
dure was technically unsuccessful, with no resolution of the
pressure gradient across the renal transplant anastomosis
after angioplasty. Surgical revision was recommended in
this patient because there was signiﬁcant elastic recoil. Six
patients underwent urgent interventions for external iliac
artery dissection and bleeding requiring a covered stent
(n¼ 1), acute renal failure secondary to iliac vein thrombosis
(n ¼ 1), acute renal failure secondary to a large AVF in the
early postoperative period after a combined liver-kidney
transplant (n ¼ 1), bleeding pseudoaneurysm requiring
embolization (n ¼ 1), and hypertensive crisis with ﬂash
pulmonary edema (n ¼ 2).
Four of the 15 patients treated for worsening renal
function had associated RV-HTN. The pathologies in
this group included eight transplant anastomotic stenoses
that all underwent PTA. There were six proximal iliac
stenoses, of which two required unilateral angioplasty,
three required bilateral angioplasty (one after recanaliza-
tion of the occluded common iliac artery [CIA]), and
one requiring bilateral CIA stents. In addition, one patientpresented with deep venous thrombosis causing obstruc-
tion of allograft outﬂow requiring lysis over 3 days, fol-
lowed by therapeutic anticoagulation.
In the group that underwent interventions for wors-
ening hypertension as the primary indication for endovas-
cular intervention, six patients underwent PTA for
stenosis of their transplant anastomoses. Five patients had
proximal iliac artery stenosis, four of whom underwent
unilateral PTA, and one patient had unilateral CIA stent-
ing. Two of the PTA procedures extended down to the
external iliac artery with preservation of ﬂow in the hypo-
gastric artery.
In the third group, structural anomalies were seen on
noninvasive imaging, which was the primary indication for
intervention. This group comprised ﬁve AVFs and two pseu-
doaneurysms that were embolized using a single catheter or
coaxial microcatheter for superselective embolization. All
procedures were performed with 0.018-inch microcoils.
None of the embolization patients had any loss of transplant
parenchyma after the procedure. Four of the ﬁve AVFs were
antecedently related to renal transplant graft biopsy speci-
mens to rule out rejection. The pseudoaneurysms were at
the transplant anastomoses, with one presenting shortly
after surgery, and the other was a late presentation. One
patient required a covered stent for iliac artery dissection
in the early postoperative period after renal transplant in
the setting of active bleeding.
The PTA/stenting procedures were done for signiﬁ-
cant pressure gradient (>15 mm Hg SBP or >10 mm
Table I. Demographic and preoperative data
Variables
No. (%)
(N ¼ 34)
Males 21 (61.80)
Race
Caucasian 25 (73.5)
African American 7 (20.6)
Hispanic 2 (5.9)
ASA class
2 5 (14.7)
3 22 (64.7)
4 7 (20.6)
Urgent/emergency cases 6 (17.7)
Comorbidities
Diabetes 14 (41.2)
Hypertension 31 (91.2)
Hyperlipidemia 24 (70.6)
Coronary artery disease 8 (23.5)
Congestive heart failure 9 (26.5)
Smoking
Current smokers 5 (14.7)
Former smokers 9 (26.5)
Never smokers 20 (58.8)
Peripheral arterial disease 6 (17.7)
ASA, American Society of Anesthesiologists.
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stenosis on angiogram. A marked improvement of
average 6 standard deviation pressure gradient of 53.7 6
32.7 mm Hg was seen across the stenotic renal transplant
and proximal iliac lesions, with a preprocedure vs postpro-
cedure gradient of 64.5 6 37.4 vs 11.2 6 10.6 mm Hg in
the group that underwent intervention for worsening renal
function. In contrast, patients with a primary indication of
RV-HTN showed a lesser degree of improvement in pres-
sure gradient (23.9 6 17.5 mm Hg; P ¼ .017), with mean
preprocedure and postprocedure gradients of 30.6 6 19.1
and 6.7 6 5.2 mm Hg, respectively.
Hypertension was prevalent in 91% of the population,
with the mean 6 standard error number of antihyperten-
sive medications at 2.6 6 0.3 (range, 0-5). In patients
who had RV-HTN as a primary indication or in association
with worsening creatinine, the mean number of antihyper-
tensives used preprocedure was signiﬁcantly higher than
postprocedure (3.6 vs 2.9; paired t-test, P ¼ .01), as well
as compared with patients without RV-HTN (Table III).
The dosage of antihypertensive medications was reduced
in one-third of the patients. Overall, improvement in
control of hypertension was seen in eight of the 15 patients
(53.3%; P ¼ .004). Interestingly, analysis of only the 11
patients who were primarily intervened on for RV-HTN
(after exclusion of the patients with associated worsening
creatinine) revealed that the improvement in the number
of antihypertensive medications was no longer signiﬁcant,
and only 36% of those patients showed improvement in
their blood pressure control (P > .05).
Improvement or stabilization of renal function
occurred in 67% of patients with worsening renal function
as the primary indication for intervention along withresolution of their complications such as heart failure and
edema. They had a mean decline (Dchange) in serum creat-
inine of 1.2 6 1.0 mg/dL compared with only 0.03 6
0.2 mg/dL in the RV-HTN group and 0.4 6 0.5 mg/
dL in the structural anomalies group (Table IV). There
was no association with use of contrast or CO2 for angiog-
raphy and change in serum creatinine.
There were no periprocedural deaths, and overall
30-day morbidity was 17.6%. The only access-related com-
plication was a groin hematoma that was self-limiting.
Other morbidities were related to the general medical
condition of the patients, including pneumonia (n ¼ 1),
sepsis (n ¼ 2), hemolytic uremic syndrome with throm-
botic thrombocytopenic purpura (n ¼ 1), and urine leak
after transplant (n ¼ 1). However, none of the patients
with RV-HTN presented with any 30-day morbidity
compared with the other patients (P ¼ .02). Six patients
were diagnosed with AIOD through this process of inves-
tigation of their transplant allograft function, making the
prevalence of PAD w35% in the entire cohort.
Mean follow-up was 4.2 years. Five patients required
one intervention, and two patients required multiple inter-
ventions, which included three transplant anastomotic
angioplasties, three transplant stents, two iliac PTAs, and
one CIA stenting procedure, with an overall restenosis
rate of 17.6%. Most patients had routine noninvasive
duplex imaging follow-up studies up to 3 years in addition
to clinical history, examination, and laboratory workup
every 3 months for the ﬁrst year, followed by every
6 months, and subsequently were followed up clinically.
Noninvasive imaging was repeated if clinically indicated
during that time.
Overall primary patency was 69% at 10 years. Primary
patency was better based on the primary indication group
of renovascular hypertension (90% at 10 years) compared
with a 10-year patency rate of 64% for the worsening renal
function group, although not statistically signiﬁcant
(P ¼ .27). There was no signiﬁcant difference based on
the pathology of the lesion, with TRAS and proximal iliac
stenosis having primary patency of 70% and 79%, respec-
tively. The primary assisted patency for the entire cohort
was 89% at 10 years. With secondary interventions, primary
assisted patency was 93% in the worsening renal function
group vs 100% for the RV-HTN group at 10 years. The
need for secondary interventions was not signiﬁcantly
different in the groups based on the indication for initial
intervention or location of primary lesion.
Patency of the renal or proximal iliac artery did not
correlate with renal transplant graft salvage, because eight
patients (23%) went on to develop renal failure and
required dialysis, over an average of 4 years. Two patients
underwent transplant nephrectomy. There was no signiﬁ-
cant difference in need for post-transplant dialysis and
transplant nephrectomy in patients with and without recur-
rent stenoses needing reintervention. Six patients died
during follow-up: two died of transplant failure, one of
metastatic melanoma, and the other deaths were due to
unknown causes.
Table II. Indications, pathology, and interventions for endovascular interventions for salvage of renal transplant allografts
Primary indication No. Pathology Interventions
Worsening renal functiona 15 8 transplant anastomotic stenoses PTA
6 proximal iliac stenoses Iliac PTA w/wo stent
1 iliac vein thrombosis occluding outﬂow Iliac vein lysis
Renovascular hypertension 11 6 transplant anastomotic stenoses PTA
5 proximal iliac stenoses Iliac PTA w/wo stent
Structural anomalies 8 5 arteriovenous ﬁstulas Embolization
2 pseudoaneurysms Embolization
1 EIA dissection Covered stent placement
EIA, External iliac artery; PTA, percutaneous transluminal angioplasty; w/wo, with or without.
aAssociated hypertension, n ¼ 4.
Table III. Use of antihypertension medications in the study cohort
Variable
All patients (N ¼ 34),
mean (SE)
RV-HTN (n ¼ 15),
mean (SE)
No RV-HTN (n ¼ 18),
mean (SE) P
Anti-HTN meds, No.
Preprocedure 2.6 (0.3) 3.6 (0.2) 1.8 (0.3) .0005
Postprocedure 2.2 (0.2) 2.9 (0.2) 1.7 (0.3) .003
Decrease in meds 0.4 (0.2) 0.7 (0.2) 0.055 (0.2) .03
HTN, Hypertension; RV, renovascular; SE, standard error.
Table IV. Serum creatinine levels (in mg/dL) in the study cohort
Variable
All patients
(N ¼ 34),
mean (SE)
Worsening renal
function (n ¼ 15),
mean (SE)
RV-HTN
(n ¼ 11),
mean (SE)
Structural anomalies
(n ¼ 8),
mean (SE) P
Serum creatinine
Preprocedure 2.6 (1.4) 2.9 (1.2) 1.3 (0.4) 3.6 (1.5) .0002
Postprocedure 1.9 (1.2) 1.7 (0.6) 1.2 (0.4) 3.2 (1.8) .0006
Decrease in level 0.6 (0.9) 1.2 (1.0) 0.03 (0.2) 0.4 (0.5) .0007
HTN, Hypertension; RV, renovascular; SE, standard error.
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survival for the RV-HTN group, but during the entire dura-
tion of follow-up, no signiﬁcant differences were found in
transplant allograft survival based on indication for endovas-
cular intervention (log-rank test, P ¼ .36; Fig 2). However,
comparing transplant allograft function in patients with RV-
HTN (with or without worsening renal function) at the
time of endovascular intervention showed 100% transplant
allograft salvage at 5 years compared with 59% in the rest
of the patients with no RV-HTN (log-rank test, P ¼ .03;
Fig 3). There was no signiﬁcant difference in long-term
renal transplant allograft survival based on underlying
pathology (TRAS, proximal iliac stenosis, or other).
DISCUSSION
With better immunosuppression and increased volume
of renal transplantation, older patients now comprise
a signiﬁcant portion of the transplant population. Because
the survival of renal transplant patients has increased, natu-
rally, increases in atherosclerotic disease processes are beingidentiﬁed in this population. Presently, the incidence of
PAD in renal transplant patients is 1.8%.8 The overall inci-
dence of PAD (aortoiliac, femoropopliteal, or tibial disease)
is 2.3% in our transplant registry. The incidence of arterial
stenosis requiring endovascular intervention for transplant
salvage was only 1.4%; therefore, we do not recommend
routine surveillance unless indicated by worsening graft
function. Of note, some patients were recognized with
new AIOD due to hypertension and worsening renal allo-
graft function and did not present with claudication or crit-
ical limb ischemia, the classic manifestations of PAD.
Solitary transplant kidney with TRAS is akin to the
single kidney model described by Goldblatt9 in 1934.
The ischemia due to decreased perfusion of the kidney
stimulates renin secretion leading to vasoconstriction and
increased intravascular volume. This response is ampliﬁed
in transplant patients due to a lack of compensatory
response by a contralateral kidney. Proximal iliac stenosis
mimics the effect of renal artery stenosis for transplant
recipients by inducing the renin-angiotensin system
Fig 2. Renal transplant allograft survival by primary indication of
endovascular intervention: worsening renal function (renalFxn),
renovascular hypertension (HTN), or structural anomalies.
Fig 3. Renal transplant allograft survival by presence of renovas-
cular hypertension (HTN) at the time of the initial endovascular
intervention.
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few studies and case reports have described the effect of
proximal iliac artery stenosis on renal transplant,10-12 but
long-term effects of treatment of AIOD on renal graft
function and RV-HTN has not been studied or compared
with TRAS. Our study monitored patients for 10 years
with a mean follow-up of 4.2 years. The patency of inter-
ventions for TRAS and proximal iliac lesions was similar
at 5 and 10 years (w70% to 79%). The location of the
pathology did not inﬂuence the clinical beneﬁt seen as
much as the primary indication for intervention and pres-
ence of RV-HTN at presentation.
Endovascular interventions for TRAS have been
described in various series.4,13-15 The incidence of TRAS
is reported from 1% to 23%16 and typically occurs #3 years
of renal transplantation. In our series, the mean time to
endovascular intervention for renal transplant anastomotic
interventions was much shorter (5 months) than for iliac
artery interventions (32 months). This is probably due to
the different pathology of the disease because TRAS are
more likely due to neointimal hyperplasia and scarring,
whereas atherosclerotic disease progression is responsible
for the proximal iliac lesions. The restenosis rate in our
series was similar to that described in literature (15% to
20%).15
Endovascular treatment of arterial stenosis (TRAS or
proximal iliac lesions) has been met with varied
success.4,7,11-16 Most of the reports focus on TRAS, and
thus, very limited data exist regarding success of treatment
of proximal iliac disease in renal transplant allograft
survival. The ambiguity in the clinical beneﬁt may be attrib-
uted to wide patient selection, unclear indications of PTA
with and without stenting, treatment of lesions in the
absence of true RV-HTN or worsening renal function,
limited follow-up data, and lack of clinical end points. In
our study, we tried to deﬁne the clinical indication in the
comparative analysis rather than focus on the location ofthe pathology. Using that approach, we saw a deﬁnitive
improvement in blood pressure control in patients who
presented with RV-HTN compared with others. Again,
in patients who underwent an endovascular procedure for
worsening renal function, we saw the maximum improve-
ment in serum creatinine levels compared with other
indications.
The maximum beneﬁt in long-term transplant allograft
survival was seen in patients with RV-HTN at their initial
presentation. The reason for this result could be potential
immunologic pathways leading to decline in graft function
in addition to the presence of arterial stenosis and its effect
on the renin-angiotensin pathway. Immunosuppression is
associated with accelerated atherosclerosis in transplant
recipients17 and may have a contributory role to the
progression of stenoses. A higher incidence of rejection
has also been reported in patients with TRAS18 and may
lead to enhanced immunologic response that results in
a decline in graft function.
The use of endovascular techniques for management of
structural abnormalities, such as AVFs and pseudoaneur-
ysms, has been beneﬁcial in avoiding open surgery in trans-
plant patients, who are at higher operative risk than the
general population. Various case reports and series have
been published regarding occurrence of AVFs after renal
transplant biopsy that need embolization.19,20 In our study,
this group was heterogeneous and included two patients
with ongoing bleeding that needed urgent interventions
with covered stent or coil embolization. The duration of
follow-up for this group was shorter (mean follow-up, 14
months) than for those patients with worsening renal func-
tion or RV-HTN as primary indications for intervention
because they resolved quickly without recurrence and did
not need further imaging after a couple of years.
One limitation of our study is that we analyzed a small
cohort; thus, multiple inferences with statistical signiﬁcance
were often not possible. In addition, the data were
JOURNAL OF VASCULAR SURGERY
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bias. Clinical information was sometimes limited from old
records or on follow-up parameters.
CONCLUSIONS
Endovascular techniques for the management of renal
transplant allograft salvage are safe and effective in short-
term control of nephropathy and hypertension, and thus,
preserve the structural integrity of the transplant allograft,
as well as long-term survival of the graft. Our data indicates
that patients with RV-HTN derive the most beneﬁt from
these interventions. Further areas of study, including delin-
eating natural history and response to treatment for AIOD
leading to transplant nephropathy and RV-HTN, as well as
in-depth studies to elucidate why RV-HTN patients did
better than others with endovascular techniques, are neces-
sary to further understand the limits of endovascular
therapy in this patient cohort.
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